In the APOLLO-B trial, 12-month treatment with patisiran resulted in preserved functional capacity, health status, and quality of life in patients with transthyretin (ATTR) cardiac amyloidosis compared with placebo.
The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.
AHA 2023 In a placebo-controlled phase 1 trial, a single dose of lepodisiran reduced Lp(a) level in a dose-dependent manner (up to 94% at 48 weeks) in individuals with elevated Lp(a) levels. The therapeutic was well-tolerated.
AHA 2023 George Bakris shares the results of the KARDIA-1 trial, in which zilebesiran, a RNAi therapeutic targeting angiotensinogen, lowers blood pressure for up to 6 months with a single subcutaneous injection.
AHA 2023 In the phase 2 KARDIA-1 trial, a single dose of the RNA interference therapeutic zilebesiran led to reductions in 24-h ambulatory systolic BP at month 3 in patients with hypertension, and these effects were sustained over 6 months.
Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.
The KARDIA 1 phase 2 trial showed a reduction in 24-h ambulatory systolic BP of greater than 15 mmHg with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo.
ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.
ESC Congress 2023 In ORION-8, long-term efficacy and safety of the PCSK9 siRNA inclisiran was assessed in a large high CV risk patient population. R. Scott Wright shares the results.
In a phase 1 study, a single dose of the siRNA zilebesiran reduced serum angiotensinogen levels and blood pressure in patients with hypertension up to 24 weeks.
The 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease has been published.
The FDA has approved expanded indication for inclisiran, enabling broader use of inclisiran in patients with primary hyperlipidemia with increased CV risk, but who have not had a CV event.